Literature DB >> 7438329

Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.

M Salimtschik, H T Mouridsen, J Loeber, E Johansson.   

Abstract

The present study was undertaken to elucidate (1) the relationship between plasma concentration of medroxyprogesterone acetate (MPA; Clinovir) administered by the PO and the IM routes; and (2) the relationship between dose and plasma concentration of MPA. Nineteen patients entered the study. In each patient the plasma concentration was monitored after a single PO and IM administration of MPA at the following dose levels: 100 mg (5 patients), 400 mg (5 patients), 800 mg (5 patients) and 1,200 mg (4 patients). The time interval between PO and the IM administration was 1 week. The results show (1) a very large interindividual variation in plasma concentration; (2) increasing plasma concentration with both PO and IM dose; (3) after the IM administration plasma levels are steady or increase slightly within the test period; (4) after the oral administration the concentration increases rapidly to reach a peak before 2-7 h and subsequently decreases again, peak concentrations being 2-10 times higher than after IM administration; and (5) within the test periods the plasma concentration x time (0-168 h) is comparable with the two methods of administration.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438329     DOI: 10.1007/bf00255272

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

1.  High dose medroxyprogesterone-acetate treatment in advanced mammary carcinoma. A phase II investigation.

Authors:  W Mattsson
Journal:  Acta Radiol Oncol Radiat Phys Biol       Date:  1978

2.  High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.

Authors:  M De Lena; C Brambilla; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Treatment of breast cancer with medroxyprogesterone acetate.

Authors:  F M Muggia; P A Cassieth; M Ochoa; F A Flatow; A Gellhorn; G A Hyman
Journal:  Ann Intern Med       Date:  1968-02       Impact factor: 25.391

4.  Hormonal therapy in cancer of the breast. XXIV. Effect of corticosterone or medroxyprogesterone acetate on clinical course and hormonal excretion.

Authors:  A Segaloff; M Cuningham; B F Rice; J B Weeth
Journal:  Cancer       Date:  1967-10       Impact factor: 6.860

5.  Radioimmunoassay of oestrone and oestradiol in human and bovine peripheral plasma.

Authors:  L E Edqvist; E D Johansson
Journal:  Acta Endocrinol (Copenh)       Date:  1972-12

6.  Measurement of medroxyprogesterone acetate (Provera ) by radioimmunoassay.

Authors:  J C Cornette; K T Kirton; G W Duncan
Journal:  J Clin Endocrinol Metab       Date:  1971-09       Impact factor: 5.958

7.  Progestin therapy of breast cancer: comparison of agents.

Authors:  B A Stoll
Journal:  Br Med J       Date:  1967-08-05

8.  Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.

Authors:  D J Klaassen; E F Rapp; W E Hirte
Journal:  Cancer Treat Rep       Date:  1976-03

9.  A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.

Authors:  F Pannuti; A Martoni; G R Lenaz; E Piana; P Nanni
Journal:  Cancer Treat Rep       Date:  1978-04

10.  High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.

Authors:  G R Cuna; A Calciati; M R Strada; C Bumma; L Campio
Journal:  Tumori       Date:  1978-04-30
View more
  11 in total

Review 1.  Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.

Authors:  A D Stockdale; A Y Rostom
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

2.  Plasma concentrations of medroxyprogesterone acetate and megesterol acetate during long-term follow-up in patients treated for metastatic breast cancer.

Authors:  A A Miller; R Becher; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

3.  Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients.

Authors:  H van Veelen; P H Willemse; D T Sleijfer; J J Pratt; W J Sluiter; H Doorenbos
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer.

Authors:  D W Hedley; M Christie; R P Weatherby; I D Caterson
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies.

Authors:  M Izuo; Y Iino; K Endo
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

6.  The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer.

Authors:  H C Blossey; H H Bartsch; D Kanne; J Koebberling; G A Nagel
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology.

Authors:  V Tamassia; A Battaglia; F Ganzina; A M Isetta; G Sacchetti; F Cavalli; A Goldhirsch; K Brunner; G Bernardo; G Robustelli della Cuna
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.

Authors:  P A Canney; M Dowsett; T J Priestman
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640

9.  Hormonal, chemical and thermal inhibition of spermatogenesis: contribution of French teams to international data with the aim of developing male contraception in France.

Authors:  Jean-Claude Soufir
Journal:  Basic Clin Androl       Date:  2017-01-13

10.  An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.

Authors:  J R Johnson; T J Priestman; K Fotherby; K A Kelly; S G Priestman
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.